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Background: Previous studies have shown that electroacupuncture (EA) has a significant effect on acute pain, but
it has not solved the clinical problem of the chronification of acute pain. Diffuse noxious inhibitory controls (DNIC)
function as a reliable indicator to predict the risk of chronic pain events. DNIC function in knee osteoarthritis (KOA)
patients has been demonstrated to gradually decrease during the development of chronic pain. The purpose of
this study is to conduct a randomized, controlled clinical trial to determine if EA can repair impaired DNIC function
and thus prevent chronification of the acute pain of KOA.
Methods/Design: This is a multicenter, single blind, randomized, controlled, three-arm, large-scale clinical trial. A
total of 450 KOA patients will be randomly assigned to three groups. The strong EA group will receive EA with
high-intensity current (2 mA < current < 5 mA) at the ipsilateral ‘Neixiyan’ (EX-LE5), ‘Dubi’(ST35), ‘Liangqiu’(ST34) and
‘Xuehai’ (SP10). The weak EA group will receive EA with low-intensity current (0 mA < current < 0.5 mA) on the same
acupoints. The sham EA group will receive EA with low-intensity current (0 mA < current < 0.5 mA) with fine needles
inserted superficially into the sites 2 cm lateral to the above acupoints. The patients will be treated with EA once a
day, 30 minutes per session, in 5 sessions per week, for 2 weeks. In order to determine the best stage of KOA for effective
EA intervention, patients within the treatment groups also will be divided into four stages. The primary outcomes are Visual
Analog Scale (VAS), DNIC function and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
Clinical assessments will be evaluated at baseline (before treatment) and after 5 to 10 sessions of treatment.
Discussion: This trial will be helpful in identifying whether strong EA is more effective than weak EA in
reversing chronification of acute pain through repairing the impaired DNIC function and in screening for the
best stage of KOA for effective EA intervention.
Trial registration: Chinese Clinical Trial Registry Number: ChiCTR-ICR-14005411. The date of registration is 31 October 2014.
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Figure 1 Trial flow chart.
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Knee osteoarthritis (KOA) is one of the most common
types of osteoarthritis and often occurs in older adults
[1]. Patients with KOA often suffer from pain around
the joints and have a high risk of chronification of acute
pain. Chronification of acute pain means that persistent
acute pain without positive intervention can damage the
nervous system and then change into intractable chronic
pain [2]. In recent years, a series of clinical randomized
controlled trials indicated that electroacupuncture (EA)
is effective for treating various painful diseases such as
KOA in the acute phase but did not solve the clinical
problems of the chronification of acute pain of KOA [3].
The concept of diffuse noxious inhibitory controls
(DNIC) has attracted particular attention in the past de-
cades, which means under normal conditions, pain can
be attenuated by a conditioning noxious stimulus to a
remote body region [4]. DNIC function is now regarded
as a reliable indicator for predicting the risk of chronic
pain [5,6]. DNIC function in KOA patients has been
shown to gradually decrease with the development of
chronic pain [7]. Thus, we hypothesized that the process
of chronification of acute pain may be related to grad-
ually impaired DNIC function, and EA may prevent the
occurrence of chronification of acute pain by improving
DNIC function.
The aim of this study is to explore whether EA can
reverse impaired DNIC function by reducing the pain
of KOA during the process of chronification of acute
pain. Moreover, we will screen for the best EA thera-
peutic regimen, which will include optimizing the in-
tensity of the current used in the EA stimulation and
determining the best stage for effective EA interven-
tion using a randomized controlled clinical trial.
Methods/Design
Ethics
The study is in accordance with the Declaration of
Helsinki, it has been approved by the Chinese Ethics
Committee of Registering Clinical Trials (reference:
ChiECRCT-20140035), and it also has been registered
with Chinese Clinical Trial Registry (ChiCTR-ICR-
14005411). Before randomization, all patients will be
expected to sign a written informed consent.
Design
A randomized, controlled, three-arm, large-scale trial to
compare two true EA groups (strong EA and weak EA)
with a sham EA group will be undertaken in this study
[8]. Four hundred and fifty KOA patients will be re-
cruited from the following six hospitals: the Combined
Traditional Chinese and Western Medicine Hospital Af-
filiated to Huazhong University of Science and Technology,
The Third Hospital of Wuhan, Central Hospital of Wuhan,Union Hospital Affiliated to Tongji Medical College of
Huazhong University of Science and Technology, Wuhan
Hospital of Traditional Chinese Medicine, and The Fifth
Hospital of Wuhan. Patients will be randomized in a ratio
of 1:1:1 to the strong EA group, weak EA group and sham
EA group. After submitting informed consent and being
randomized, patients will receive 10 sessions of EA treat-
ment over a period of 2 weeks, with a treatment frequency
of 5 sessions per week. Each session will last 30 minutes.
Patients will be asked to accept assessments at baseline, as
well as at the end of the first and second weeks of the
treatment phase. Time points and groups are shown in
Figure 1.
Randomization and blinding
Patients who meet the inclusion criteria will be randomly
assigned to one of three groups (strong EA, weak EA or
sham EA) in a ratio of 1:1:1 using a computer-generated
random allocation sequence through the stratified block
randomization method of SAS version 9.1.3 (SAS Institute
Inc., USA). The randomization will be performed by an
independent research assistant, who will inform the acu-
puncturists of the treatment assignments by mobile mes-
sage. Allocation concealment will not be exposed until the
final data analysis report is completed.
Figure 2 The points used in the trial. The lines refer to acupoints
of ‘Liangqiu’ (ST34) and ‘Dubi’ (ST35) on the lateral side of the knee,
and ‘Xuehai’ (SP10) and ‘Neixiyan’ (EX-LE5) on the medial side of
the knee. The points lateral to the above four acupoints refer
to non-acupoints.
Shen et al. Trials  (2015) 16:131 Page 3 of 8To maintain blinding, each patient will have needles (true
or sham) inserted into his/her ipsilateral leg. The needles
are connected to an EA apparatus, and the patients can feel
electric stimulation. Strong and weak EA groups will be
acupunctured on four acupoints. The sham EA group will
be acupunctured on four non-acupoints without ‘De-qi’.
In this clinical trial process, the patients, statisticians
and the evaluators for the statistical data and outcomes
are blind to the treatment allocation. However, the blind
method is not used by acupuncturists in the implemen-
tation of EA manipulation because it is not feasible to
conceal allocation from them.
Patients
Study population
Patients will be recruited from among acupuncture inpa-
tients and clinics of six hospitals with a target sample
size of 450 subjects. The trial will be ongoing from
September 2014 to September 2016.
Inclusion criteria
Patients who meet the clinical criteria for KOA formulated
by the American College of Rheumatology (ACR) will be
considered for inclusion [9]. According to the ACR, clinical
KOA is defined as knee pain and at least three out of seven
of the following criteria: patient is older than 50 years of
age, morning stiffness lasts less than 30 minutes, crepitus
is present, bony enlargement is apparent, bony tenderness
is present, no palpable warmth is present, and presentation
is suggestive of a radiological osteophyte.
Exclusion criteria
The exclusion criteria are as follows:
1. Patient has had an adverse reaction to acupuncture
or is unwilling to accept acupuncture treatment.
2. Patient conforms to the inclusion criteria, but does
not follow prescribed treatment, which decreases the
curative effects of EA so that it cannot be judged, or
patient has incomplete information that may
interfere with his/her ability to accurately judge the
effects of his/her treatment.
3. Patient has accompanying severe cardiovascular,
cerebral, hepatic, renal, or hemopoietic diseases [10].
4. Patient has inflammatory arthritis such as rheumatoid
arthritis, gouty arthritis, etcetera or other diseases that
may affect the condition of the knees [11].
5. Patient is pregnant, attempting to become pregnant
or lactating [10].
6. Patient has a mental disease [11].
Recruitment of patients
Two schemes will be used to recruit patients with KOA.
The first is to recruit patients in the outpatient andinpatient departments from the six hospitals. The chief
physicians of the acupuncture and rehabilitation depart-
ment in each hospital will screen eligible patients ac-
cording to the inclusion/exclusion criteria with the help
of research assistants. Moreover, potential patients in
local communities and out-hospital clinics will be re-
cruited by advertisements through posters, leaflets,
newspapers, and so on. After being screened and found
to meet the inclusion criteria, the patients will be in-
cluded only if they agree to join in every procedure of
the trial willingly and provide written informed consent.
Interventions
Electroacupuncture group
According to the Traditional Chinese Medicine meridian
theory of treating pain of KOA [11,12], patients in the
strong and weak EA treatment groups will be treated
with EA on ipsilateral acupoints of ‘Neixiyan’ (EX-LE5),
‘Dubi’(ST35), ‘Liangqiu’(ST34) and ‘Xuehai’ (SP10) once
a day (Figure 2). The sterile, disposable Hwato needles
used in this trial are made in Suzhou, China. Patients
are positioned on the bed, supported by two pillows
under the knees and instructed to assume a comfortable
position and not to move during the 30-minutes stimu-
lation period.
After the local area has been disinfected, the needles
(30-gauge with an outer diameter of 0.32 mm and a
length of 50 mm) will be inserted at a depth of 25 to
40 mm vertically and ‘De-qi’ (the acupuncture sensation
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will be achieved in the strong and weak EA groups
through lifting and thrusting combined with twirling
and rotating the needles. Direct current and continuous
wave will be delivered with a medical EA apparatus
(model G9805, Shanghai, China), at 2 Hz frequency and
0.5 ms pulse width for 30 minutes. EX-LE5 will be con-
nected to ST35, and SP10 will be connected to ST34
with a pair of electrodes [10,13]. Different stimulation
intensities will be allocated to the strong EA and weak
EA groups. The strong EA group will receive the max-
imum tolerable intensity of current (2 mA < current <
5 mA). However, patients in the weak EA group will re-
ceive low-intensity current (0 mA < current < 0.5 mA),
and they will be instructed to ask the doctor to stop the
increase in intensity when the sensations of current
occur. After the intervention period, all needles and the
EA apparatus will be removed (Table 1).
Sham EA group
In the sham EA group, a sterile, disposable, fine and
short needle (35-gauge needle with an outer diameter of
0.20 mm and a length of 25 mm) will be used and
inserted superficially (to an approximate depth of 5 to
10 mm) into the sites of the non-acupoints 2 cm lateral
to the above four acupoints (Figure 2). However, the
‘De-qi’ sensation will not be intentionally elicited in this
group. Electrical stimulation will be delivered with low-
intensity current (0 mA < current < 0.5 mA) at 2 Hz fre-
quency and 0.5 ms pulse width for 30 minutes, which is
the same as for the weak EA group (Table 1).
Education of practitioners
All EA and sham EA treatments will be performed by
acupuncturists who have been qualified for at leastTable 1 Details of each group
Group Acupoints Stimulation paramete
Strong EA group Neixiyan Direct current, continu
Maximum tolerable int




Weak EA group Neixiyan Stimulation indexes an





Sham EA group The sites are 2 cm lateral
to the above
Fine needles will be in
with low-intensity curr
four points
Note: EA, electroacupuncture.3 years and hold Chinese medicine practitioner licenses
from the Ministry of Health of the Peoples Republic of
China. Each acupuncturist will take a pretrial training
course for this clinical study. The chief physicians will
train all acupuncturists and observe their techniques
periodically to ensure standardization. In addition, all
study protocols and details, including the recording
method for the case report form, outcome assessment
methods, and monitoring process, will be standardized
among the six centers by the research assistants.
Outcome assessments
Primary outcome measurements
The primary outcome measurements are the Visual
Analog Scale (VAS), DNIC function and the Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC).
VAS is an internationally recognized pain scale. It is a
100-mm line ranging from 0 (no pain) to 100 (pain as
bad as it could be) [14].
The prediction of chronification of acute pain can be
indicated by DNIC function, which means that pain elic-
ited by a noxious stimulus applied to a given body site
can be attenuated by application of a conditioning nox-
ious stimulation to another, even distant body region
[15]. DNIC function will be measured according to the
procedure shown in Figure 3. On the Ashi-point (pain
spot) of the affected knee, the research assistant will
apply a 180-g von Frey filament (bending it so that it
forms a 45-degrees angle with the skin) three to five
times within a 1-cm-diameter circle (Figure 3A). The pa-
tients will be asked to rate the intensity of pain as VAS1
[5], which is the induced mechanical pain score of the
affected knee. Then, the patients will be asked to im-
merse the contralateral hand, including the wrist, intors
ous wave, at 2 Hz frequency and with 0.5 ms pulse width for 30 minutes.
ensity of current will be delivered, 2 mA < current < 5 mA. EX-LE5 will be
SP10 will be connected to ST34 with a pair of electrodes.
d acupoint’ connections are the same as in the strong EA group, but
el the sensations of current, 0 mA < current <0.5 mA.
serted superficially into the sites 2 cm lateral to the above four points
ent as same as in the weak EA group.
Figure 3 The main procedure for the measurement of diffuse
noxious inhibitory controls (DNIC) function. A. On the Ashi-point
of the knee, a 180-g von Frey filament is used to prick three to five
times within a 1-cm-diameter circle at an angle of 45-degrees between
the filament and the skin. The patients will be asked to rate the
intensity of pain as VAS1. B.The patients will be asked to immerse
the contralateral hand, including the wrist, into nociceptive cold
water (10 to 12°C) for 1 minute, and the doctors will rate the intensity
of the 180-g von Frey filament-induced pain at the Ashi-point as
VAS2. DNIC = (VAS1-VAS2)/VAS1.
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rate the intensity of the pain induced by the 180-g von
Frey filament on the Ashi-point as VAS2 (Figure 3B).
For healthy people, the conditioning cold noxious stimu-
lation can activate the descending inhibitory system of
the spinal cord. VAS2 is used to detect the induced
mechanical pain score of the affected knee after condi-
tioning with the cold noxious stimulation on the contra-
lateral hand. Finally, DNIC function will be assessed by
measuring the difference in pain ratings before and after
immersion (DNIC = (VAS1-VAS2)/VAS1). Thus, the de-
creased ratio in pain scores of the affected knee before
and after the cold noxious stimulation of the hand is the
DNIC function [2,16].
WOMAC can be used as an initial assessment of the
intensity of pain and functional disability of KOA [3]. It
is a multidimensional measure of pain, stiffness, and
physical functional disability [17]. Briefly, five questions
will be asked about pain dimension at activity or rest.
The stiffness dimension includes two questions. Ques-
tions about the degree of difficulty in 17 different activ-
ities will be asked for the physical functional disability
dimension. All 24 questions will be listed in a numerical
rating scale ranging from 0 (no symptoms) to 3 (maximum
symptoms). Doctors need to help patients perform
the self-assessment, collect the total score from the
24 questions and record it.
Secondary outcome measurements
The secondary outcome measurements are Numerical
Rating Scale (NRS), Emotional Scale (ES), Present Pain
Intensity (PPI) and range of motion (ROM).
The NRS of pain is a scale containing the numbers
from 1 to 10 on a straight line to measure the magnitude
or intensity of pain [18]. It has been shown to have a
good predictive validity and has been used to measurethe effect of EA on the pain of KOA [12]. All subjects
participating in the study will be asked to select a num-
ber from 1 to 10 with the nearest 0.5 interval, to repre-
sent their maximal OA-induced knee pain in the most
recent 2 to 3 days.
Pain, whether acute or chronic, can affect a patient’s
emotions. Under normal circumstances, emotion can be
distinguished according to four levels, measured as ES:
Excellent (0 to 2, face is peaceful, and the patient re-
sponds freely), Good (3 to 5, face remains indifferent,
and the patient responds to instruction), General (5 to 8,
anxiety or depression apparent, face shows some pain,
and patient barely answers), and Poor (8 to 10, face
clearly shows pain, with moaning and forced posture,
and patient fails to answer).
PPI is also one of the clinical tools most commonly
used to help patients express the intensity of pain. It
moves from 0 to 5, indicating the following levels of pain
according to number: no pain, mild discomfort, discom-
fort, terrible pain and extreme pain.
ROM indicates the maximum range of joint activities.
Determination of ROM is a basic step in assessing
muscle, bone and neurological damage. It is one of the
indicators used to evaluate the scope of damage and de-
gree of joint movement function, and it can be measured
with the help of protractor whose axis is placed on the
fibular capitulum, with the fixed arm parallel to the long
axis of the femur and with the moving arm parallel to
the long axis of the fibula while in a prone position. The
normal range of motion of the knee is ‘0 to 135°’.Sample size
According to a previous study and our pilot data, the
sample size calculation assumed an average DNIC in-
crease percentage of 30% for the strong EA group [19].
The DNIC increase percentage for the weak EA group
and sham EA group are assumed to be 20% and 15%, re-
spectively. It is assumed that 15% of the trial patients
will be lost to attrition. With this scenario, 150 patients
need to be allocated to each treatment group to establish
a difference among the treatments at a 5% level and with
a power of 90% [20].Data analysis
Data with normal distribution will be presented as
means ± SEM. We will use a one-way analysis of vari-
ance (ANOVA) or a two-way ANOVA to determine
the overall effect of EA. The Post hoc test (Newman
Keuls test) will then be used to determine the statis-
tical differences among individual groups. A P value of
less than 0.05 will be considered statistically signifi-
cant. Data showing an abnormal distribution will be
analyzed by the Wilcoxon signed-rank test.
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the best for each of the different stages of KOA,
patients in the three EA groups will be further
divided according to four different stages of KOA:
1. The acute pain stage group. The pain of KOA has
been ongoing for less than 6 months.
2. The early chronic pain stage group. The pain of
KOA has been ongoing for 6 months to 3 years.
3. The medium-term chronic pain stage group. The
pain of KOA has been ongoing for 3 to 5 years.
4. The advanced chronic pain stage group. The
pain of KOA has been ongoing for more than
5 years (Figure 4A).
The effect of EA on the different stages of KOA will
be observed, and the stage with the best response to
EA intervention will be discussed. Furthermore, in yet
another comparison, we will divide all patients into the
four stages and then compare the effects of the strong,
weak and sham EA groups within the different stages
separately (Figure 4B).
Discussion
The aim of this trial is to use EA intervention to inhibit
chronification of the acute pain of KOA by reversing theFigure 4 Data analysis chart. A. We will divide the three electroacupunct
stage where the EA intervention will be most effective. B. We will divide al
sham EA separately within the different stages. The Visual Analog Scale (VA
and McMaster Universities Osteoarthritis index (WOMAC), Numerical Rating
motion (ROM) will be measured by the procedure outlined in the chart.damage to the DNIC function. Completion of this trial
will help to identify whether EA with high-intensity
current (strong EA) is more effective than EA with low-
intensity current (weak EA) and whether EA applied at
an early stage of KOA will be more effective than that at
a later stage of KOA.
We will establish two treatment groups and one
control group in this randomized controlled trial. Since
the primary consideration of this trial is to clarify
whether EA is effective in preventing chronification of
the acute pain of KOA, we will use sham EA as a
control to rule out the placebo effect. In the sham EA
group, acupuncture needles are shallowly inserted into
non-acupoint locations to rule out the effect of acupoint.
Because most of the KOA patients are familiar with the
sensation of EA, they could realize that it is the sham EA
if they cannot feel any current from the apparatus.
Therefore, we will use a low intensity of electrostimulation
to exclude a placebo effect.
Acupoints of EX-LE5, ST34, ST35, and SP10 are located
around the knees, which have been regarded as the most
common and effective acupoints for use in treating KOA
in many high-quality trials [11,21]. Since 2 Hz is the
optimized EA frequency for the relief of inflammatory
pain, we chose the 2 Hz as the best frequency of EA to
treat KOA in this study [22].ure (EA) groups into four different stages to screen separately for the
l patients into four stages and compare the effects of strong, weak and
S), diffuse noxious inhibitory control (DNIC) function, Western Ontario
Scale (NRS), Emotional Scale (ES), Present Pain Intensity (PPI), range of
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transmission of nociceptive signals and is another pain
perception methodology recently used to study patho-
physiology of various pain disorders because it reflects
the function of the endogenous pain system [23,24]. This
pain-modulating process is the neurophysiological basis
for the well-known phenomenon where ‘pain inhibits
pain’ from remote areas of the body [5]. The continuous
pain input will impair the DNIC function and then de-
crease antinociceptive activity from the supraspinal
structures, which may result in the occurrence of chronic
pain [25]. Numerous studies have demonstrated that
DNIC may be involved in the analgesic mechanism of
acupuncture [26,27]. However, no study has used DNIC
function to screen for the best EA intensity and for the
best stage of chronification of acute pain for an effective
EA intervention.
To screen for the optimal intensity of EA for improv-
ing DNIC function, the effect of strong EA and weak EA
will be compared. EA with low-intensity current (less
than 1 mA) has been demonstrated to mainly excite
large fibers (Aβ fiber), which may not activate the
DNIC function [28]. Instead, this innocuous stimula-
tion may only exert an analgesic effect through the
spinal mechanism of gate control theory [29]. In con-
trast, EA with high-intensity current (more than
2 mA) excited thin fibers (A δ and/or C fibers) and
may activate DNIC function [30]. Thus, we will compare
the effect of strong EA and weak EA on repairing im-
paired DNIC function to screen for the best EA intensity
to prevent chronification of the acute pain of KOA. We
hypothesize that both strong EA and weak EA may have
some pain-reducing and inflammation-relieving effects,
which will be assessed with VAS, WOMAC, NRS, ES, PPI
and ROM. However, strong EA may be more effective in
improving DNIC function and, thus, in reversing the
chronification of acute pain [28].
Moreover, we also will try to determine the best stage
of KOA for EA intervention. DNIC function is the func-
tion of the endogenous analgesic system [16]. In other
words, the process of gradually decreased DNIC func-
tion is also the process of transforming acute pain to
chronic pain. In this process, if patients receive EA inter-
vention as soon as possible, it is possible that the chroni-
fication of pain in KOA patients will be prevented.
However, at the later stages of chronic pain, peripheral
and central sensitization will likely irreversibly damage
the endogenous analgesic system function and com-
pletely impair DNIC function [2]. At that point, EA may
not be as effective. So, we will further divide the KOA
patients according to the stage of the disease. We hope
to find the best stage for the use of EA to reverse the
impaired DNIC function and prevent the chronification
of acute pain.This project will not only increase knowledge on the
effects of treating KOA with EA, but also may contribute
a solution to the difficult problem of the chronification of
acute pain, and promote the clinical application of EA
analgesia.
Trial status
This trial is currently recruiting patients.
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